AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%
Amgen Inc.
Amgen Inc. (NASDAQ: AMGN) is a biotechnology business focused on assisting people with serious illnesses. The company creates, manufactures, and sells a wide range of human treatments. It has grown into one of the world's most successful independent biotechnology companies, reaching millions of patients globally and developing a pipeline of potentially game-changing drugs. Its most well-known medications are ENBREL, Prolia, Otezla, XGEVA, Neulasta, Aranesp, Repatha, and KYPROLIS.
Why Should Investors Book Profit?
Valuation Methodology: Price/Earnings Per Share Multiple Based Relative Valuations
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
AMGN's share price has inclined 19.74% in the past six months and is currently leaning towards the higher band of the 52-week range of USD 198.64 to USD 261. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 220.88.
Considering the company's long cash cycle, weak liquidity profile, current valuation, and associated risks. We recommend a "Sell" rating on the stock at the current price of USD 254.65, up 1.03% as of April 11, 2022, at 09:01 AM PDT.
1-Year Technical Price Chart (as of April 11, 2022, at 09:01 AM PDT). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.